GSK has stopped development of camlipixant, its chronic cough drug acquired in a $2 billion Bellus Health deal, after Phase 3 results missed nearly all goals. The termination closes a blockbuster opportunity GSK had targeted for 2026, while GSK said it will continue Phase 2 work in irritable bowel syndrome.